Integrating Drug Substance and Drug Product Development to Accelerate Clinical Timelines

Drug substance (DS) and drug product (DP) development are often executed as sequential and independent activities, with critical decisions made in isolation. While this approach can yield APIs that meet quality specifications, it frequently introduces downstream risks—manifesting as formulation challenges, stability failures, and ultimately delays in clinical timelines.

This case study demonstrates how Aragen’s integrated DS–DP development strategy enabled a clinical-stage biotechnology company to overcome recurring formulation challenges, realign its development approach, and recover valuable time by designing drug substance attributes with drug product performance as the end goal.

A clinical-stage biotech company engaged Aragen after encountering persistent challenges during drug product development. Although the drug substance consistently met release specifications, the program faced several recurring issues:

• Variability in dissolution performance
• Repeated stability failures
• Content uniformity inconsistencies across batches

Despite multiple formulation attempts, these challenges remained unresolved, placing clinical timelines at significant risk.

Through a thorough assessment, Aragen identified that critical drug substance decisions had been made without evaluating their downstream impact on drug product performance. This lack of DS–DP integration led to late-stage formulation issues—at a point where corrective actions are both complex and costly.

A comprehensive DS–DP evaluation revealed that upstream decisions were directly driving downstream failures:

• Solid-state variability: APIs from different vendors exhibited polymorphic differences, resulting in inconsistent dissolution
• Particle size misalignment: Poor control of particle size distribution negatively impacted flow properties and blend uniformity
• Residual solvent impact: Solvent levels within ICH limits still accelerated degradation pathways in the final product
• Excipient incompatibility: Reactivity between an amine-containing API and lactose contributed to instability
• Salt form limitations: The selected salt improved solubility but was suboptimal for manufacturability and long-term stability

Collectively, these issues highlighted the risks of developing drug substance without fully considering downstream formulation, manufacturability, and stability requirements.

To address these challenges, Aragen implemented a fully integrated DS–DP development model, ensuring that decisions related to solid-state properties, particle characteristics, and chemical attributes were aligned with formulation and regulatory requirements from the outset.

Key elements of the approach included:

• Comprehensive solid-state characterization to ensure consistent polymorphic control
• Particle size distribution (PSD) optimization linked to flow, blending, and content uniformity
• Salt screening strategies balancing solubility, manufacturability, and stability
• Joint forced degradation studies spanning both DS and DP
• Reformulation strategies to eliminate excipient incompatibilities

A guiding principle was established across the program:
Every drug substance decision must clearly address its impact on drug product performance and regulatory outcomes.

This integrated framework enabled seamless alignment across chemistry, formulation, engineering, and risk management functions—creating a unified development strategy

Technical Outcomes

• Optimized API with controlled polymorphic form and particle size distribution
• Robust formulation delivering consistent dissolution and content uniformity
• Elimination of key degradation pathways
• A scientifically justified and regulatory-ready DS–DP linkage strategy

Program Impact

• Early identification and mitigation of compatibility and stability risks
• Elimination of late-stage reformulation cycles
• Improved clarity in regulatory planning
• Recovery of approximately 2–3 months in the overall development timeline

Figure 1: Integrated DS–DP development timeline illustrating parallel execution and early decision alignment to recover critical development time.

Aragen’s ability to integrate chemistry, particle science, formulation development, engineering, and manufacturing within a single ecosystem enables robust and execution-ready development strategies.

Key differentiators include:

• End-to-end non-GMP and GMP drug substance capabilities supporting over 100 programs annually
• Deep expertise in solid-state science, particle engineering, and process safety
• Phase-appropriate development with rapid scale-up readiness

By designing drug substance with drug product success as the ultimate objective, Aragen enables partners to de-risk development and advance clinical programs with confidence.

Connect today with Aragen to strengthen DS–DP integration early in development—improving manufacturability, stability, and regulatory confidence.